<産業資料/調査レポートの題名> 2022年7月17日

世界の遺伝子治療市場:ベクター別[非ウイルス(オリゴヌクレオチド)、ウイルス(レトロウイルス(ガンマレトロウイルス、レンチウイルス))、アデノ随伴]、疾患別(がん、神経疾患)、デリバリー方法別(In Vivo、Ex Vivo)、地域別


◆英文タイトル:Gene Therapy Market by Vectors [Non-viral (Oligonucleotides), Viral (Retroviral (Gammaretroviral, Lentiviral)), Adeno-associated], Indication (Cancer, Neurological Diseases), Delivery Method (In Vivo, Ex Vivo), Region - Global Forecast to 2024

1 Introduction (Page No. – 16)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitation
1.6 Stakeholders
2 Research Methodology (Page No. – 19)
2.1 Research Data
2.2 Secondary Data
2.2.1 Secondary Source
2.3 Primary Data
2.4 Market Size Estimation
2.4.1 Bottom-Up Approach
2.4.2 Bottom-Up Approach for Non-Viral Vectors and Viral Vectors Market
2.4.3 Growth Forecast
2.5 Market Breakdown and Data Triangulation
2.6 Assumptions for the Study
3 Executive Summary (Page No. – 25)
4 Premium Insights (Page No. – 28)
4.1 Gene Therapy Market Overview
4.2 North America: Market, By Vector (2018)
4.3 Geographical Snapshot of the Market
5 Market Overview (Page No. – 30)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 High Incidence of Cancer and Other Target Diseases
5.2.1.2 Product Approvals
5.2.1.3 Funding for Gene Therapy Research
5.2.2 Opportunities
5.2.2.1 Strong Product Pipeline
5.2.3 Challenges
5.2.3.1 High Cost of Treatments
6 Gene Therapy Market, By Vector (Page No. – 35)
6.1 Introduction
6.2 Non-Viral Vectors
6.2.1 Oligonucleotides
6.2.1.1 North America Accounted for the Largest Share of the Oligonucleotides Segment
6.2.2 Other Non-Viral Vectors
6.3 Viral Vectors
6.3.1 Retroviral Vectors
6.3.1.1 Gamma-Retroviral Vectors
6.3.1.1.1 The Availability of A Wide Range of Gamma-Retroviral Vectors Supports the Growth of This Market
6.3.1.2 Lentiviral Vectors
6.3.1.2.1 North America Accounted for the Largest Share of the Lentiviral Vectors Segment
6.3.2 Adeno-Associated Virus Vectors
6.3.2.1 Possible Applications in In Vivo Applications Have Driven Interest in Adeno-Associated Virus Vectors
6.3.3 Other Viral Vectors
7 Gene Therapy Market, By Indication (Page No. – 44)
7.1 Introduction
7.2 Neurological Diseases
7.2.1 Neurological Diseases Account for the Largest Share of the Market
7.3 Cancer
7.3.1 Cancer is Expected to Show the Highest Growth in This Market
7.4 Hepatological Diseases
7.4.1 Increasing Prevalence of Hepatitis B Infections Will Support Market Growth
7.5 Duchenne Muscular Dystrophy
7.5.1 North America Accounted for the Largest Share of the Dmd Gene Therapy Segment
7.6 Other Indications
8 Gene Therapy Market, By Delivery Method (Page No. – 50)
8.1 Introduction
8.2 In Vivo Gene Therapy
8.3 Ex Vivo Gene Therapy
9 Gene Therapy Market, By Region (Page No. – 53)
9.1 Introduction
9.2 North America
9.2.1 US
9.2.1.1 The US Dominates the Global Market
9.2.2 Canada
9.2.2.1 Growing Burden of Cancer Will Support Market Growth in Canada
9.3 Europe
9.3.1 Germany
9.3.1.1 Germany Accounted for the Largest Share of the Market in Europe
9.3.2 France
9.3.2.1 Increasing Cancer Incidence Supports Market Growth
9.3.3 UK
9.3.3.1 Rising Incidence of Melanoma Will Drive Demand in the UK
9.3.4 Italy
9.3.4.1 High Incidence of Targeted Diseases and Increasing Per Capita Healthcare Spending Will Drive Market Growth in Italy
9.3.5 Spain
9.3.5.1 Non-Viral Vectors Dominate the Spanish Market, By Vector
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.1.1 Japan Dominates the APAC Market for Gene Therapy
9.4.2 China
9.4.2.1 Rising Prevalence of Cancer and Established Base for Gene Therapy are Supportive Factors in China
9.4.3 Rest of APAC
9.5 Rest of the World
10 Competitive Landscape (Page No. – 89)
10.1 Overview
10.2 Market Share Analysis, 2018
10.3 Key Strategies
10.4 Competitive Leadership Mapping (2018)
10.4.1 Visionary Leaders
10.4.2 Innovators
10.4.3 Dynamic Differentiators
10.4.4 Emerging Companies
11 Company Profiles (Page No. – 95)
(Business Overview, Products Offered, Recent Developments & MnM View)*
11.1 Biogen
11.2 Gilead Sciences, Inc.
11.3 Amgen, Inc.
11.4 Novartis AG
11.5 Orchard Therapeutics Plc
11.6 Spark Therapeutics, Inc. (A Part of ýHoffmann-La Roche)
11.7 Molmed S.P.A.
11.8 Anges, Inc.
11.9 Bluebird Bio, Inc.
11.10 Human Stem Cells Institute (HSCI)
11.11 SIBIONO Genetech Co., Ltd.
11.12 Shanghai Sunway Biotech Co., Ltd
11.13 Uniqure N.V.
11.14 Gensight Biologics S.A.
11.15 Celgene Corporation (A Bristol-Myers Squibb Company)
11.16 Cellectis
11.17 Sangamo Therapeutics
11.18 Mustang Bio
11.19 AGTC (Applied Genetic Technologies Corporation)
11.20 Poseida Therapeutics, Inc.
*Details on Business Overview, Products Offered, Recent Developments & MnM View Might Not Be Captured in Case of Unlisted Companies.
12 Appendix (Page No. – 123)
12.1 Insights From Industry Experts
12.2 Discussion Guide
12.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
12.4 Available Customization
12.5 Related Reports
12.6 Author Details


LINEで送る
Share on LinkedIn
このエントリーをはてなブックマークに追加
Bookmark this on BuzzURL
Bookmark this on Yahoo Bookmark